microRNA Diagnostics and Therapeutics
Ed. by Sempere, Lorenzo
1 Issue per year
After a decade of the discovery of this regulatory class of short non-coding RNA genes, microRNAs have brought about conceptual innovations and technological advances to virtually all fields of biological and biomedical sciences. In this relatively short period of time, thanks to intense, competent and competitive investigations, we have witnessed how basic research findings on specific microRNAs have already reached patients as phase II clinical trials. Collectively, these investigations have provided a solid foundation for the utilization of microRNA-based strategies in management and treatment of human disease.
Recognizing the extraordinary potential and dimension of this rapidly expanding field, microRNA Diagnostics and Therapeutics (miRNA Dx/Rx) publishes original research and reviews on development, implementation and clinical application of microRNA-based diagnostic and therapeutic tools. miRNA Dx/Rx covers various areas of human disease, including cardiovascular and metabolic diseases, neurodegenerative conditions, and cancer. miRNA Dx/Rx focuses on diagnostic applications in clinical specimens and demonstration of therapeutic validity of microRNA-based approaches in animal models and advances.
Aims and Scope
Why subscribe and read
microRNA Diagnostics and Therapeutics (miRNA Dx/Rx) serves as a central portal to integrate the most up-to-date and relevant data on microRNA diagnostic and therapeutic studies. Since methodological, experimental and intellectual challenges and solutions for microRNA-based diagnostic and therapeutic applications are likely to present both commonalities across disciplines and also peculiarities in specific diseases, miRNA Dx/Rx provides a convenient and authoritative platform to gain quick access to this multidisciplinary knowledge.
microRNA Diagnostics and Therapeutics (miRNA Dx/Rx) offers fast, constructive and comprehensive peer-review for a professional and satisfactory experience for submitting authors. miRNA Dx/Rx provides a visible platform for authors’ studies to reach a broad audience of academic and industrial scientists, pathologists, clinicians, and other health care providers carrying out research on and/or interested in the development, implementation and application of microRNA-based diagnostic and therapeutic tools for management and treatment of human disease.
miRNA Dx/Rx’s relevance and visibility relies on the quality of the accepted publications and on the active engagement of its Editorial Advisory Board (EAB) with the scientific community. Internationally-recognized scholars and investigators, who are leaders in key areas of the microRNA field, constitute the EAB of miRNA Dx/Rx.
- DE GRUYTER OPEN
- Emerging Science
- Type of Publication:
- Researchers in the field of genetics.
Submission of Manuscripts
Instructions for Authors
Manuscripts should be submitted to the journal via email to the Journal Editor at email@example.com.
Authors are suggested to follow Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals from the International Committee of Medical Journal Editors (ICMJE).
Manuscript submitted to this journal should:
- contain original work - not published elsewhere in any medium (in the whole or in part) by the authors or anyone else and not under consideration for publication in any other medium;
- focus on the aims and scope of the journal;
- be clearly and correctly written - should contain all essential features of a scientific publication that is easy to understand for the target audience;
- written in English - attention to detail of the language will avoid severe misunderstandings which might lead to rejection of the paper;
- be delivered in electronic format.
The journal accepts the following publication formats:
- Research Articles
- Communications and Rapid Communications
- Reviews and Mini-Reviews
- Letters to the Editor and Amendments
It is important that authors include a cover letter with their manuscript. Please explain why you consider your manuscript as suitable for publication in the journal, why will your paper inspire the other members of your field, and how will it drive research forward.
The letter should contain all important details such as:
- your full name (submitted by)
- full title of article and short title
- full list of authors with affiliations
- e-mail of the corresponding author
- contact address, telephone/fax numbers of the corresponding author
- number of attached files, if there is more than one
- status: new, reviewed or accepted (with reference ID if reviewed or accepted)
Cover letter should explicitly state that the manuscript (or one with substantially the same content, by any of the authors) has not been previously published in any language anywhere and that it is not under simultaneous consideration or in press by another journal. If related work has been submitted, then we may require a preprint to be made available. Reviewers will be asked to comment on the overlap between the related submissions.
Manuscripts that have been previously rejected, or withdrawn after being returned for modification, may be resubmitted if the major criticisms have been addressed. The cover letter must state that the manuscript is a resubmission, and the former manuscript number should be provided.
Conflict of interest declaration
To ensure fair and objective decision-making, authors must declare any associations that pose a conflict of interest in connection with evaluated manuscripts (see Editorial Policy for details). Authors are encouraged to fill in the ICMJE Conflicts of Interest Form (available here) and send it in the electronic format to the Journal Editor.
Open Access License
Authors have to sign an Open Access License that is available on the journal webpage. We encourage the authors to send the signed license along with the manuscript. Please note, that no article will be published unless the Open Access License is signed.
We accept submission of text, tables and figures as separate files or as a composite file. For your initial submission, we recommend you upload your entire manuscript, including tables and figures, as a single PDF file. If you are invited to submit a revised manuscript, please provide us with individual files: an editable text and publication-quality figures.
- Text files can be submitted in the following formats: MS Word - standard DOCUMENT (.DOC) or RICH TEXT FORMAT (.RTF); PDF (not applicable for re-submitted or accepted manuscripts, see below)
- Tables should be submitted as MS Word or PDF (not applicable for re-submitted or accepted manuscripts, see below). Please note that a straight Excel file is not an acceptable format
- Graphics files can be submitted in any of the following graphic formats: EPS; BMP; JPG; TIFF; GIF or PDF. Please note that Powerpoint files are not accepted
Post acceptance, text files of the revised manuscript and tables are required for use in the production.
Authors should clearly indicate location of tables and figures in the text if these elements are given separately or at the end of the manuscript. If this information is not provided to the editorial office, we will assume that they should be left at the end of the text.
For further instructions, please carefully follow the guidelines described in Instructions for Authors.
Abstracting & Indexing
microRNA Diagnostics and Therapeutics is covered by the following services:
- Baidu Scholar
- CNKI Scholar (China National Knowledge Infrastructure)
- DOAJ (Directory of Open Access Journals)
- EBSCO (relevant databases)
- EBSCO Discovery Service
- Elsevier - EMBASE
- Elsevier - Reaxys
- Genamics JournalSeek
- Google Scholar
- KESLI-NDSL (Korean National Discovery for Science Leaders)
- Naviga (Softweco)
- Polish Scientific Journals Database
- Primo Central (ExLibris)
- Summon (Serials Solutions/ProQuest)
- Ulrich's Periodicals Directory/ulrichsweb
- WanFang Data
- WorldCat (OCLC)
Lorenzo F. Sempere, Van Andel Research Institute, Grand Rapids, MI, USA
Andrea Caporali, Queen's Medical Research Institute, University of Edinburgh, UK
Xi (Hill) Liu, National Cancer Institute (NCI), National Institutes of Health (NIH), USA
Benjamin Ory, Nantes University School of Medicine, France
Editorial Advisory Board
George Calin, MD Anderson Cancer Center, USA
Stephen Y. Chan, Brigham and Women's Hospital/Harvard Medical School, USA
Jose R. Conejo-Garcia, Wistar Institute, USA
Ethan Dmitrovsky, Dartmouth Medical School, USA
Aurora Esquela-Kerscher, Eastern Virginia Medical School, USA
Jason Fish, University Health Network, Canada
Sarah Freemantle, Dartmouth Medical School, USA
Carlos Fernandez-Hernando, NYU Langone Medical Center, USA
Christopher Hammell, Cold Spring Harbor Laboratory, USA
Scott Hammond, University of North Carolina, Chapel Hill, USA
Annick Harel-Bellan, CEA Saclay, France
Jingfang Ju, Stony Brook University Medical Center, USA
Rajesh Katare, University of Otago, New Zealand
Fabio Martelli, IRCCS-Policlinico San Donato, Milan, Italy
Eric Miska, University of Cambridge, UK
Kenoki Ohuchida, Kyushu University, Japan
Cho Chi Shing, Queen Elizabeth Hospital, UK
Thomas Schmittgen, The Ohio State University, USA
Eva van Rooij, Miragen Therapeutics, USA
Joanne Weidhaas, Yale University, USA
DE GRUYTER OPEN
Bogumiła Zuga 32A Str.
01-811 Warsaw, Poland
T: +48 22 701 50 15
Lorenzo F. Sempere